Emergent BioSolutions to Acquire Protein Sciences’ Phase III Recombinant Flu Vaccine Candidate, FluBlok(R), and Related Novel Platform Technology
Emergent BioSolutions Inc. (NYSE:EBS) and Protein Sciences Corporation (PSC), based in Meriden, Connecticut, announced today that the two companies have entered into an asset purchase agreement under...
Emergent BioSolutions Reports Financial Results for First Quarter 2008
Continued delivery of BioThrax(R) doses under current HHS contract drives 62 percent increase in first quarter revenue -- Continued investment in pipeline through internally generated cash flows --...
Emergent BioSolutions Acquires Advanced Recombinant Protective Antigen Anthrax Vaccine Candidate and Technology
Emergent BioSolutions Inc. (NYSE: EBS) announced today that it has completed the acquisition of all assets and rights related to a recombinant protective antigen (rPA) anthrax vaccine product...
Emergent BioSolutions to Release First Quarter 2008 Financial Results and Conduct a Conference Call On May 7, 2008
Emergent BioSolutions Inc. (NYSE:EBS) announced today that it will report financial results for the first quarter of 2008 on Wednesday, May 7, 2008, before market open. Company management will host a...
Emergent BioSolutions to Hold Annual Meeting of Stockholders Wednesday, May 21, 2008 at 10:00 am Eastern
Emergent BioSolutions Inc. (NYSE:EBS) announced today that it will hold its Annual Meeting of Stockholders on Wednesday, May 21, 2008 beginning at 10:00 am Eastern Time at the Crowne Plaza Hotel, 3...
Emergent BioSolutions to Present at the Cowen and Company 28th Annual Health Care Conference on March 18, 2008
Emergent BioSolutions Inc. (NYSE:EBS) announced today that the company will be presenting at the Cowen and Company 28th Annual Health Care Conference on Tuesday, March 18, 2008 at 11:00 AM Eastern at...
Emergent BioSolutions Reports Financial Results for 2007
Record revenues of $182.9 million -- Net income of $22.9 million or $0.79 per share; sixth consecutive year of profitability -- Year end cash balance of $105.7 million -- Financial outlook for 2008...
Emergent BioSolutions Acquires Monoclonal Anthrax Product Candidate
Emergent BioSolutions Inc. (NYSE:EBS) announced that today it completed the acquisition of a group of anthrax monoclonal antibodies from AVANIR Pharmaceuticals (NASDAQ:AVNR), including AVANIR's lead...
Emergent BioSolutions Appoints Dr. W. James Jackson as Chief Scientific Officer
Emergent BioSolutions Inc. (NYSE: EBS) announced today that W. James Jackson, Ph.D., has been appointed chief scientific officer, effective immediately. Dr. Jackson will report directly to Fuad...
Emergent BioSolutions to Release Full Year 2007 Financial Results and Conduct a Conference Call on March 7, 2008
Emergent BioSolutions Inc. (NYSE: EBS) announced today that it will report financial results for the full year 2007 on Friday, March 7, 2008, before market open. Company management will host a...
Emergent BioSolutions to Present at BIO CEO & Investor Conference on February 11, 2008
Emergent BioSolutions Inc. (NYSE:EBS), announced today that the company will be presenting at the 10th Annual BIO CEO & Investor Conference on Monday February 11, 2008 at 1:15 PM Eastern at the...
Emergent BioSolutions and Ninebio Sdn. Bhd. Announce Joint Venture in Malaysia
Emergent BioSolutions (NYSE: EBS) and Ninebio Sdn. Bhd. ("9Bio") today announced the formation of a joint venture in Malaysia that will focus on creating critical biologics infrastructure and...